WO2012074676A3 - Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto - Google Patents

Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto Download PDF

Info

Publication number
WO2012074676A3
WO2012074676A3 PCT/US2011/059577 US2011059577W WO2012074676A3 WO 2012074676 A3 WO2012074676 A3 WO 2012074676A3 US 2011059577 W US2011059577 W US 2011059577W WO 2012074676 A3 WO2012074676 A3 WO 2012074676A3
Authority
WO
WIPO (PCT)
Prior art keywords
dpp
glp
inhibitors
agonists
compositions
Prior art date
Application number
PCT/US2011/059577
Other languages
French (fr)
Other versions
WO2012074676A2 (en
Inventor
Nitika Gupta
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of WO2012074676A2 publication Critical patent/WO2012074676A2/en
Publication of WO2012074676A3 publication Critical patent/WO2012074676A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

This disclosure relates to GLP-1 pathway agonists and DPP -2 inhibitors and uses related thereto. In certain embodiments, the disclosure relates to methods of improving organ transplants and preventing ischemic injury. In certain embodiments the disclosure relates to organ, cell, or tissue preservation solutions comprising compositions disclosed herein.
PCT/US2011/059577 2010-11-09 2011-11-07 Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto WO2012074676A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41151810P 2010-11-09 2010-11-09
US61/411,518 2010-11-09

Publications (2)

Publication Number Publication Date
WO2012074676A2 WO2012074676A2 (en) 2012-06-07
WO2012074676A3 true WO2012074676A3 (en) 2012-08-16

Family

ID=46172461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/059577 WO2012074676A2 (en) 2010-11-09 2011-11-07 Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto

Country Status (1)

Country Link
WO (1) WO2012074676A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258639B2 (en) 2014-05-06 2019-04-16 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
EP3160491A4 (en) * 2014-06-25 2018-01-17 GlaxoSmithKline LLC Pharmaceutical compositions
LT3250202T (en) 2015-01-27 2021-06-25 SciPharm S.à r.l. Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
CN116270980A (en) * 2022-12-27 2023-06-23 江苏诺泰澳赛诺生物制药股份有限公司 Pharmaceutical composition containing GLP-1 analogue and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BADET, L. ET AL.: "Effect of IGL-1, a new preservation solution, on kidney grafts (a pre-clinical study)", TRANSPL. INT., vol. 17, no. 12, May 2005 (2005-05-01), pages 815 - 821 *
ZAOUALI, M. A. ET AL.: "Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution", LIVER TRANSPL., vol. 16, no. 9, September 2010 (2010-09-01), pages 1098 - 1111 *
ZAOUALI, M. A. ET AL.: "Relevance of epidermal growth factor to improve steatotic liver preservation in IGL-1 solution", TRANSPLANT. PROC., vol. 42, no. 8, October 2010 (2010-10-01), pages 3070 - 3075 *

Also Published As

Publication number Publication date
WO2012074676A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2009105294A3 (en) Topical compositions and methods for whitening skin
WO2012021845A3 (en) Improved hematopoietic stem and progenitor cell therapy
WO2010021714A3 (en) Improved cell composition and methods of making the same
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
GEP20156376B (en) Solid herbicide compositions with built-in adjuvant
WO2009089494A3 (en) Pharmaceutical compositions
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2008085221A3 (en) Therapeutic use of cd31 expressing cells
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
WO2012077077A8 (en) Fungicidal mixtures
ZA201008398B (en) An electrochemically active composition,methods of making,and uses thereof
AR081681A1 (en) METHODS AND COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF b-GALACTOCEREBROSIDASA
WO2007095594A3 (en) Methods and compositions for enhancing engraftment of hematopoietic stem cells
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
CA2801009C (en) Native wharton's jelly stem cells and their purification
EP2629799A4 (en) Topical base and active agent-containing compositions, and methods for improving and treating skin
WO2018211454A3 (en) Cryoprotectant and/or cryopreservant composition, methods and uses thereof
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
EP2152279A4 (en) Use of biological surfactant as anti -inflammatory agent and tissue preservative solution.
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2011042902A3 (en) Microcapsules comprising benzoyl peroxide and topical compositions comprising them
WO2009047568A3 (en) In vitro preservation of living animal cells and compounds suitable for use in the preservation of living animal cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846031

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11846031

Country of ref document: EP

Kind code of ref document: A2